Table 2 Baseline patient characteristics

From: Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)

  

Docetaxel/cisplatin

Docetaxel/irinotecan

χ2 text

No. of patients

 

51

57

 

Gender

Male/female

37/14

38/19

P=0.537

Age (years)

Median

62

60

 
 

Range

39–74

42–77

 

PS

0/1

15/36

15/42

P=0.830

Histology

Adenocarcinoma

36

44

P=0.520

 

Squamous cell carcinoma

13

9

 
 

Others

2

4

 

Disease stage

Illb/IV

11/40

14/43

P=0.820

Brain metastasis

(+)/(−)

4/47

11/46

P=0.086

  1. PS=performance status.
Back to article page